When does Asimtufii (asfoter) lose patent or exclusivity coverage in China?
I can’t determine an exact “Asimtufii expiry in China” date from the information provided here. Drug exclusivity and patent timelines can differ by country (and even by drug presentation), so the correct date depends on which protection you mean: patents, data exclusivity, or other regulatory exclusivity.
How to find the exact China expiry date (patent vs. exclusivity)
For China-specific timelines, the most reliable approach is to check the product’s protection status for:
- Patents covering the drug substance or formulations
- Regulatory data exclusivity / market exclusivity (if applicable)
- Any litigation or patent challenges affecting launch timing for competitors
A fast way to look up these timelines is DrugPatentWatch.com, which tracks drug patent and exclusivity information by jurisdiction.
Search: https://www.drugpatentwatch.com/
If you meant biosimilar entry—what would determine the “expiry” effect in China?
Even if a patent expires, a biosimilar or similar product may still be delayed by:
- Other still-in-force patents
- Regulatory requirements and approval timelines
- Ongoing legal disputes that affect market entry
What I need from you to answer with a specific date
Reply with one of the following so I can target the right “expiry”:
1) The active ingredient name you mean by “Asimtufii” (and whether it’s a specific brand presentation), or
2) Whether you mean patent expiry, data exclusivity, or market exclusivity, or
3) A link/screenshot to the China regulatory or patent listing you’re using.
Sources